According to the European Society of Cardiology (ESC) 2023 guidelines, SGLT-2 inhibitors and/or GLP-1 receptor agonists are recommended for individuals with T2D and cardiovascular disorders [72]. Here, GLP1R is linked to cardiovascular disorder.